{
    "code": 0,
    "data": [
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Earnings Call Transcript for meeting held on 22 January 2026",
            "news_id": "885074c4-762f-445d-bb07-cb873d0aaade",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=34b1a767-1439-465b-924c-69b545d3a86b.pdf",
            "news_date": "2026-01-27 15:12:22",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Earnings Call Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Earnings Call Transcript for meeting held on 22 January 2026",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=34b1a767-1439-465b-924c-69b545d3a86b.pdf",
            "news_date": "2026-01-27 15:12:22"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "In continuation to our earlier intimation dated January 15 2026 Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 the audio recording of the Jagsonpal Pharmaceuticals Limited Q3 FY26 Earnings Conference Call held on January 22 2026 at 5:00 P.M. for discussion of Q3 FY26 Financial Results is available on the Companys website at below link: https://www.jagsonpal.com/investor-relations/earning-calls.\r\nWe request you to take the above on record.",
            "news_id": "49b102df-1230-4ea5-9d26-d2a66ebea9da",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=493a7558-6ba4-4844-ac7d-e4c1be128755.pdf",
            "news_date": "2026-01-22 18:55:54",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "In continuation to our earlier intimation dated January 15 2026 Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 the audio recording of the Jagsonpal Pharmaceuticals Limited Q3 FY26 Earnings Conference Call held on January 22 2026 at 5:00 P.M. for discussion of Q3 FY26 Financial Results is available on the Companys website at below link: https://www.jagsonpal.com/investor-relations/earning-calls.\r\nWe request you to take the above on record.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=493a7558-6ba4-4844-ac7d-e4c1be128755.pdf",
            "news_date": "2026-01-22 18:55:54"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Pursuant to Regulation 47 of SEBI (LODR) 2015 please find enclosed copies of advertisement published on January 22 2026 in Business Standard (English) and Business Standard (Hindi) newspaper providing extracts of Unaudited Financial Results of the Company for the quarter and nine months ended December 31 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1a397325-8efe-465f-9c0c-e32f5072ad09.pdf",
            "news_date": "2026-01-22 09:37:20"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Press release and investor presentation for the quarter and nine months ended December 31 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=981ce57f-34e9-402c-a674-be68d8abf0a3.pdf",
            "news_date": "2026-01-21 19:14:06"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Press release and investor presentation for the quarter and nine months ended December 31 2025",
            "news_id": "1f5f337a-bd3f-4eb1-90db-94acbe1c805a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=50f29d76-4e8a-446b-a571-60c71bae4969.pdf",
            "news_date": "2026-01-21 19:12:18",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Press release and investor presentation for the quarter and nine months ended December 31 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=50f29d76-4e8a-446b-a571-60c71bae4969.pdf",
            "news_date": "2026-01-21 19:12:18"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting Held On January 21 2026 Along With Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025",
            "news_body": "Pursuant to Regulation 33 of SEBI (LODR) 2015 we would like to inform you that the board of directors at its meeting held today inter-alia considered and approved the unaudited financial results for the quarter and nine months ended December 31 2025",
            "news_id": "9d377561-4fdb-47ca-84fb-5ed7b2c7d281",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ab3a9cd6-ad17-4e78-85c8-d56f4e664a8e.pdf",
            "news_date": "2026-01-21 17:33:30",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "Outcome",
            "descriptor": "Financial Results",
            "caption": "Outcome Of Board Meeting Held On January 21 2026 Along With Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025",
            "news_body": "Pursuant to Regulation 33 of SEBI (LODR) 2015 we would like to inform you that the board of directors at its meeting held today inter-alia considered and approved the unaudited financial results for the quarter and nine months ended December 31 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ab3a9cd6-ad17-4e78-85c8-d56f4e664a8e.pdf",
            "news_date": "2026-01-21 17:33:30"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held On January 21 2026 Along With Unaudited Financial Results For The\r\nQuarter And Nine Months Ended December 31 2025",
            "news_body": "Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board of\r\nIndia (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that the Board\r\nof Directors at its Meeting held today inter-alia considered and approved the Unaudited Financial Results for the quarter\r\nand nine months ended December 31 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e0cef19f-ba8c-453e-a1a2-c1653364dc3b.pdf",
            "news_date": "2026-01-21 17:08:43"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that the Company as a part of its investors engagement activities has scheduled a conference call with the Analysts / Investors on Thursday January 22 2026 to discuss its Q3 FY26 financial results. The Conference call details is attached as Annexure.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ca112ba1-6bb1-4d7d-b5c1-a91c2010b7e3.pdf",
            "news_date": "2026-01-15 16:46:39"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Intimation Of Board Meeting",
            "news_body": "Jagsonpal Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/01/2026 inter alia to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform you that the Meeting of the Board of Directors of Jagsonpal Pharmaceuticals Limited (the Company) is scheduled to be held on Wednesday January 21 2026 to consider and approve inter-alia the Unaudited Financial Results of the company for the quarter and nine months ended December 31 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e72a4e13-c990-4e42-9717-671ef91509d8.pdf",
            "news_date": "2026-01-13 16:25:58"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "news_body": "Pursuant to Regulation 74(5) of SEBI (DP)Regulations 2018 we are enclosing herewith a copy of the Certificate received from MCS Share Transfer agent limited the RTA of Company for the quarter ended December 31 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a3008bc9-ef01-4704-8916-0282544b6225.pdf",
            "news_date": "2026-01-06 17:13:57"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Allotment of ESOP / ESPS",
            "caption": "Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS",
            "news_body": "Allotment of 109180 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan 2022",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c09e7a48-4673-429b-9aa5-affe6768c479.pdf",
            "news_date": "2026-01-06 17:01:59"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Announcement Under Regulation 30 Of SEBI (LODR) 2015",
            "news_body": "Pursuant to provisions of Regulation 30 of SEBI (LODR) 2015 we hereby submit the disclosure regarding the order received from authority.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=61952f2d-7cb4-4829-abd8-7ba10b4b2424.pdf",
            "news_date": "2025-12-30 16:51:13"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "Pursuant to SEBI (PIT) Regulations 2015 the trading window for dealing in securities of Company shall remain closed  from January 01 2026 till 48 hours after declaration of unaudited  financial results for the quarter and nine months ended on December 31 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=404d84a2-b3df-4ef7-88e6-6fd9cc1e326f.pdf",
            "news_date": "2025-12-26 12:54:57"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Please find enclosed herewith copies of newspaper advertisement published on December 05 2025 informing shareholders regarding opening of special window for Re-lodgement of transfer request  of Physical shares.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4c10130b-c8bd-4075-a29c-289480cdc01e.pdf",
            "news_date": "2025-12-05 15:04:07"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that that the representatives of Jagsonpal Pharmaceuticals Ltd. will be meeting with the investors/analysts on Tuesday 25th November 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ca55fb2a-097e-4b44-a3bb-316ec12411d5.pdf",
            "news_date": "2025-11-20 20:47:31"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Allotment of ESOP / ESPS",
            "caption": "Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS",
            "news_body": "Allotment of 56571 Equity Shares under the Jagsonpal Pharmaceuticals Limited employee stock option plan 2022.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fc9a1f45-0a7e-4430-bcf0-41df2da28b6a.pdf",
            "news_date": "2025-11-18 11:39:24"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 of SEBI (LODR) Regulations 2015 Please find enclosed transcript for the jagsonpal pharmaceuticals Limited Q2 FY 2026 earnings call held on November 04 2025 at 2:00 P.M for discussion of Q2 FY26 Financial Results.",
            "news_id": "80cfe445-5a01-4c9b-bcc7-7b51ae0ca787",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=344040a4-306a-4bdd-a0cd-5345a0ea1795.pdf",
            "news_date": "2025-11-07 15:16:17",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Earnings Call Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 of SEBI (LODR) Regulations 2015 Please find enclosed transcript for the jagsonpal pharmaceuticals Limited Q2 FY 2026 earnings call held on November 04 2025 at 2:00 P.M for discussion of Q2 FY26 Financial Results.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=344040a4-306a-4bdd-a0cd-5345a0ea1795.pdf",
            "news_date": "2025-11-07 15:16:17"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Pursuant to Regulation 47 of SEBI (LODR) Regulations 2015 Please find enclosed copies of advertisement published on November 05 2025 providing extracts of Unaudited Financial results of the Company for the quarter and half Year ended September 30 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e3743723-ff24-43d2-8db0-7c83c756a300.pdf",
            "news_date": "2025-11-05 11:26:19"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 the audio recording of the Jagsonpal Pharmaceuticals Limited Q2 FY26 Earnings Conference Call held on November 04 2025 at 2:00 P.M.",
            "news_id": "83f0b935-c1bc-4964-b52a-ea24e1b95d93",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a0c50c5c-8567-451f-8344-fb186300c3a4.pdf",
            "news_date": "2025-11-04 17:09:41",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 the audio recording of the Jagsonpal Pharmaceuticals Limited Q2 FY26 Earnings Conference Call held on November 04 2025 at 2:00 P.M.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a0c50c5c-8567-451f-8344-fb186300c3a4.pdf",
            "news_date": "2025-11-04 17:09:41"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Press Release and Investor Presentation on Un- Audited Financial Results for the quarter and half year ended September 30 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3b7e04c3-b648-49bd-89ca-4a911cbf1b42.pdf",
            "news_date": "2025-11-03 19:03:01"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Press Release and Investor Presentation on Un- Audited Financial Results for the quarter and half year ended September 30 2025",
            "news_id": "aa464732-0689-46c4-ae0f-b022f1244ac1",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=69192bd4-c5b6-4b1f-810e-6e723d9822a9.pdf",
            "news_date": "2025-11-03 19:00:14",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Press Release and Investor Presentation on Un- Audited Financial Results for the quarter and half year ended September 30 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=69192bd4-c5b6-4b1f-810e-6e723d9822a9.pdf",
            "news_date": "2025-11-03 19:00:14"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025",
            "news_body": "Pursuant to regulation 30 & Regulation 33 of SEBI (LODR) Regulations 2015 Please find enclosed the Unaudited Financial results along with its Limited review report of the Company for the quarter and half year ended September 30 2025.",
            "news_id": "b114b39a-1f9c-42f8-b427-59b9306ddfd8",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1d93ae0a-c6fc-4dd9-88fb-76b017a19a39.pdf",
            "news_date": "2025-11-03 17:28:18",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "Outcome",
            "descriptor": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025",
            "news_body": "Pursuant to regulation 30 & Regulation 33 of SEBI (LODR) Regulations 2015 Please find enclosed the Unaudited Financial results along with its Limited review report of the Company for the quarter and half year ended September 30 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1d93ae0a-c6fc-4dd9-88fb-76b017a19a39.pdf",
            "news_date": "2025-11-03 17:28:18"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting",
            "news_body": "Pursuant to Regulation 30 & Regulation 33 of SEBI (LODR) Regulations 2015 we would like to inform you\r\nthat the Board of Directors at its Meeting held today inter-alia considered and approved the Unaudited Financial\r\nResults for the quarter and half year ended September 30 2025. \r\nkindly find enclosed the Unaudited Financial Results along with its Limited Review Report issued by the Statutory Auditors of the Company for the quarter and half year ended September 30 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bc4d41fe-5120-4925-9b9a-210e99b0a6af.pdf",
            "news_date": "2025-11-03 17:21:22"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Pursuant to Regulation 30 of SEBI (LODR) 2015 we wish to inform you that company has scheduled a conference call with analysts/Investor on 04 November 2025 to discuss its Q2 FY 26 Financial Results.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0bd0e881-dbf8-4c29-968b-0313a196b5aa.pdf",
            "news_date": "2025-10-29 10:47:46"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Intimation For Board Meeting.",
            "news_body": "Jagsonpal Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2025 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (LODR) 2015 it is inform you that meeting of the board of directors is scheduled be held on November 03 2025 to consider the unaudited Financial results of Company for the quarter ended September 30 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c0902ed9-03b5-4dd6-883f-a20df2bf454a.pdf",
            "news_date": "2025-10-27 17:36:40"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "news_body": "Compliance Certificate in terms of Regulation 74(5) of SEBI (Depositories & Participants) Regulations 2018 for the quarter ended September 30 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f65197e3-1e91-4613-a6ff-79ed6891ccf8.pdf",
            "news_date": "2025-10-09 13:23:43"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Allotment of ESOP / ESPS",
            "caption": "Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS",
            "news_body": "Allotment of 93445 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employees Stock Option Plan 2022",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f9ad8509-0cf1-4ec4-ba80-72b727d3017a.pdf",
            "news_date": "2025-10-07 17:20:52"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Intimation Under Regulation 30 (5) Of The SEBI (LODR) Regulations 2015",
            "news_body": "Intimation under Regulation 30 (5) of SEBI (Listing obligations and disclosure Requirements) Regulations 2015",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=36100c84-8561-44aa-bb30-2b8eb09f94a0.pdf",
            "news_date": "2025-10-07 17:11:22"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Change in Management",
            "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
            "news_body": "Intimation under Regulation 30 of SEBI (LODR) Regulations 2015 relating to Appointment of Chief Financial Officer of the Company",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=960b2891-6b82-453c-b7b3-d402b8d29174.pdf",
            "news_date": "2025-10-07 16:52:40"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "Intimation for Closure of Trading window for declaration of Unaudited Financial results for the quarter and half year ended September 30 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9a69eee2-bb0e-4d6a-9fcf-4a14c9b3c1cb.pdf",
            "news_date": "2025-09-26 15:15:17"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "Outcome",
            "descriptor": "AGM",
            "caption": "Shareholder Meeting / Postal Ballot-Scrutinizers Report",
            "news_body": "Voting Results of 46th Annual General Meeting in terms of Regulation 44 (3) of SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 and Scrutinizers Report",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cb6f0c9f-e7a0-48c6-9286-ee49f0d35fa5.pdf",
            "news_date": "2025-09-26 15:10:35"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "Outcome",
            "descriptor": "AGM",
            "caption": "Shareholder Meeting / Postal Ballot-Outcome of AGM",
            "news_body": "Proceedings of 46th Annual general Meeting (AGM) of the Company and disclosure under SEBI (Listing Obligations and disclosure Requirements) Regulations 2015",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=431cda99-76d0-4f18-bc8d-9b1325d2cc8c.pdf",
            "news_date": "2025-09-24 17:56:13"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Newspaper Publication of Corrigendum to 46th Annual Report of the Company",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c9fb579e-e146-48f8-b90f-aac01f4e43de.pdf",
            "news_date": "2025-09-20 12:15:57"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Reg. 34 (1) Annual Report",
            "caption": "Reg. 34 (1) Annual Report.",
            "news_body": "Corrigendum to the Annual Report for the Financial Year 2024-25",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6ef958cd-7cd5-4f1e-9b07-c914dc25b1a4.pdf",
            "news_date": "2025-09-19 16:46:23"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Press Release on Appointment of Mr. Amrut Medhekar as Chief Operating Officer of the Company.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f3c85f61-3645-4a26-aa97-52831896d362.pdf",
            "news_date": "2025-09-04 20:30:54"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Change in Management",
            "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
            "news_body": "Appointment of Mr. Amrut Medhekar as the Chief Operating  Officer (COO) (Senior Managerial Personnel) of the Company",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=38225939-b24e-431f-a3b1-02c7cf4247bc.pdf",
            "news_date": "2025-09-04 16:53:27"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Letter To Shareholders For Annual Report Web-Link And Path",
            "news_body": "Letter to Shareholders whose E-mail ID has not been registered with the company for accessing Annual Report and Notice of 46th Annual General Meeting of the company in accordance with Regulation 36 of SEBI (LODR)",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f007e629-8add-4f02-9d7b-1a6bbb77615f.pdf",
            "news_date": "2025-09-02 11:18:03"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Newspaper Publication of Notice of 46th Annual General Meeting and E- voting information",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7b65636d-8c7e-4b53-a8f3-0483f9f3be03.pdf",
            "news_date": "2025-09-02 11:10:09"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Business Responsibility and Sustainability Reporting (BRSR)",
            "caption": "Business Responsibility and Sustainability Reporting (BRSR)",
            "news_body": "Business Responsibility and Sustainability Report of the Company for the Financial Year 2024-25",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=64f9c133-060b-4a62-9ae4-e678583e3d52.pdf",
            "news_date": "2025-09-01 16:48:33"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Notice Of 46Th Annual General Meeting Of The Company",
            "news_body": "Notice of the 46th Annual General Meeting of the company to be held on Wednesday September 24 2025 at 3:30 P.M. (IST)",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=22f4ce55-1c11-4945-b60a-6cbfa7dbbab3.pdf",
            "news_date": "2025-09-01 16:07:38"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Reg. 34 (1) Annual Report",
            "caption": "Reg. 34 (1) Annual Report.",
            "news_body": "Notice of 46th Annual General Meeting and Annual Report for the FY 2024-25",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=371f75ec-1941-4204-a584-ce609fd2510f.pdf",
            "news_date": "2025-09-01 16:00:31"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Newspaper Advertisement- 46th Annual General Meeting (AGM) of the company to be held through Video Conferencing(VC)/ Other Audio Visual Means (OAVM) on September 24 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e523cbe3-78e0-4b3f-b82e-2eeb5ac476f5.pdf",
            "news_date": "2025-08-13 13:14:12"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Allotment of ESOP / ESPS",
            "caption": "Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS",
            "news_body": "Allotment of Equity Shares under the Jagsonpal Phamaceuticals Limited Employee Stock Option Plan 2022",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=eb3f288f-8880-48b2-bc2d-d6556ec134e7.pdf",
            "news_date": "2025-08-08 17:55:18"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Earnings call Transcript for Jagsonpal Pharmaceuticals Limited Q1FY 26 Earnings Conference call held on July 28 2025 at 3:00 P.M.",
            "news_id": "29846c10-f64e-446e-8db0-a77ec8f8dff7",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2ab02c33-adcb-4c3e-b4c8-ec9f0a89a8d2.pdf",
            "news_date": "2025-07-31 12:06:30",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Earnings Call Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Earnings call Transcript for Jagsonpal Pharmaceuticals Limited Q1FY 26 Earnings Conference call held on July 28 2025 at 3:00 P.M.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2ab02c33-adcb-4c3e-b4c8-ec9f0a89a8d2.pdf",
            "news_date": "2025-07-31 12:06:30"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio Recording of Jagsonpal Pharmaceuticals Limited Q1 FY26 Earnings Conference Call on July 28 2025 at 3:00 P.M",
            "news_id": "cfc3f7b4-347f-4124-a507-ab0c14883742",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e11c785d-3fbf-4e18-898f-4c393bea1cf6.pdf",
            "news_date": "2025-07-28 17:46:06",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio Recording of Jagsonpal Pharmaceuticals Limited Q1 FY26 Earnings Conference Call on July 28 2025 at 3:00 P.M",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e11c785d-3fbf-4e18-898f-4c393bea1cf6.pdf",
            "news_date": "2025-07-28 17:46:06"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Extracts of Unaudited Financial Results- copy of Newspaper Advertisement",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a6ff6132-e5d4-4976-b8e7-7b96ac0a3d5e.pdf",
            "news_date": "2025-07-28 11:28:45"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Revised Press release for Unaudited Financial Results for the quarter ended June 30 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b278b02d-a630-4c13-a437-30732543c835.pdf",
            "news_date": "2025-07-26 17:07:02"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Revised Investors Presentation for financial Results for the quarter ended June 30 2025",
            "news_id": "407d1222-5d08-4a87-b65e-127c0528d6c8",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a28bb2c3-a0a4-47c5-80f0-ce2bf8f80577.pdf",
            "news_date": "2025-07-26 17:05:44",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Revised Investors Presentation for financial Results for the quarter ended June 30 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a28bb2c3-a0a4-47c5-80f0-ce2bf8f80577.pdf",
            "news_date": "2025-07-26 17:05:44"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Press Release for Unaudited Financial Results for the quarter ended June 30 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e55f2909-49ae-4c9f-8cca-4b2addb005b2.pdf",
            "news_date": "2025-07-26 13:48:23"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Press Release for Unaudited Financial Results for the quarter ended June 30 2025",
            "news_id": "83ded6d8-8f19-4409-9011-0353440f2dc4",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c3721c27-a575-4b08-b2cf-52809821b11e.pdf",
            "news_date": "2025-07-26 13:45:18",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Press Release for Unaudited Financial Results for the quarter ended June 30 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c3721c27-a575-4b08-b2cf-52809821b11e.pdf",
            "news_date": "2025-07-26 13:45:18"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "Intimation",
            "descriptor": "Record Date",
            "caption": "The 46Th Annual General Meeting Of The Company Will Be Held On September 24 2025\r\n\r\nDividend- Record Date Will Be  September 12 2025\r\n",
            "news_body": "The 46th Annual General Meeting of the company will be held on September 24 2025.\r\n\r\nThe company has fixed September 12 2025 as a Record Date for determining eligibility of shareholders for payment of Dividend.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=83f485be-84b8-479f-93fe-56fef5ca49ed.pdf",
            "news_date": "2025-07-26 13:16:14"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Results- Financial Results For The Quarter Ended June 30 2025",
            "news_body": "Unaudited Financial results for the quarter ended June 30 2025",
            "news_id": "681ad9c6-0a4e-4329-b100-abc8343eb964",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=79a7aa7c-fb7f-47ff-8789-df4854540e9c.pdf",
            "news_date": "2025-07-26 13:00:49",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "Outcome",
            "descriptor": "Financial Results",
            "caption": "Results- Financial Results For The Quarter Ended June 30 2025",
            "news_body": "Unaudited Financial results for the quarter ended June 30 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=79a7aa7c-fb7f-47ff-8789-df4854540e9c.pdf",
            "news_date": "2025-07-26 13:00:49"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting Along With Unaudited Financial Results For The Quarter Ended June 30 2025",
            "news_body": "Outcome of Board Meeting Held on July 26 2025 along with the Unaudited Financial Results for the quarter ended June 30 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=269cf7f3-afd6-47f6-8a97-cc418fd89a46.pdf",
            "news_date": "2025-07-26 12:38:49"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Allotment of ESOP / ESPS",
            "caption": "Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS",
            "news_body": "Allotment of Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan 2022",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5d27fa7d-d2d9-49b5-8481-224767a8cbf1.pdf",
            "news_date": "2025-07-24 17:14:17"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Allotment of ESOP / ESPS",
            "caption": "Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS",
            "news_body": "Intimation for Grant of Employees Stock Options",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fafa4f92-7ac8-41df-b8be-289b3483dc5d.pdf",
            "news_date": "2025-07-24 17:00:14"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that the Company as a part of its investors engagement activities has scheduled a conference call with the Analysts / Investors on Monday July 28 2025 to discuss its Q1 FY26 financial results. The Conference call details is attached as Annexure.\r\n\r\nWe request you to take the above on record.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7626456f-2101-4e1b-a466-1ce391626495.pdf",
            "news_date": "2025-07-23 15:25:04"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Consideration And Approval Of Un- Audited Financial Results  For The Quarter Ended June 30 2025",
            "news_body": "Jagsonpal Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/07/2025 inter alia to consider and approve Un- Audited Financial Results for the quarter ended June 30 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=57d3e061-7c43-4979-8d27-3c4372d6303a.pdf",
            "news_date": "2025-07-23 13:19:41"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Cessation",
            "caption": "Announcement under Regulation 30 (LODR)-Cessation",
            "news_body": "Cessation of Employment of Mr. Sachin Jain Chief Financial Officer of the Company",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1f0572d9-ed0c-4ec2-9e81-f7c92f9c17d0.pdf",
            "news_date": "2025-07-08 16:56:46"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "news_body": "Compliance Certificate under Reg 74(5) of SEBI (D&P) Reg 2018 for the quarter ended on 30 June 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f31d5ab3-e711-4b08-9f88-4405c69b6747.pdf",
            "news_date": "2025-07-07 17:44:04"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "Intimation for Closure of Trading Window",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f77cd8e3-9974-44c2-a2bd-b0df996d5e50.pdf",
            "news_date": "2025-06-26 12:45:25"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "We wish to inform you that the Company will participate in Group Conference (In-Person) on 26 June 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=97fb9673-e4a7-4c7a-bf4f-5ee74c1bd2dc.pdf",
            "news_date": "2025-06-16 17:41:09"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Allotment of ESOP / ESPS",
            "caption": "Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS",
            "news_body": "Allotment of Equity Shares under the Jagsonpal Pharmaceuticals Limited Employees Stock Options Plan 2022",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=63c542ee-8a22-41bc-a4b3-2289df6602dc.pdf",
            "news_date": "2025-06-11 16:33:14"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Change in Registered Office Address",
            "caption": "Announcement under Regulation 30 (LODR)-Change in Registered Office Address",
            "news_body": "Shifting of the Registered office of the company within the local limits of the city in which the registered office of the company is situated",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=723b72fc-46e9-40ef-8e37-07c0bae52b87.pdf",
            "news_date": "2025-06-02 20:31:36"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "Compliance",
            "descriptor": "Reg.24(A)-Annual Secretarial Compliance",
            "caption": "Compliances-Reg.24(A)-Annual Secretarial Compliance",
            "news_body": "Annual Secretarial Compliance Report for the Financial year ended March 31 2025 under Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements)",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e2d4854a-a4df-4a0a-a53a-70b7abcd861a.pdf",
            "news_date": "2025-05-27 12:56:21"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Earnings Call Transcript for Jagsonpal Pharmaceuticals Limited Q4FY25 Earnings Conference Call held on May 7 2025",
            "news_id": "3a14d135-f88c-4556-92a9-fd237c300095",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f538ec5d-ba34-4c69-aec7-b824b9c0c2f1.pdf",
            "news_date": "2025-05-13 15:12:36",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Earnings Call Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Earnings Call Transcript for Jagsonpal Pharmaceuticals Limited Q4FY25 Earnings Conference Call held on May 7 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f538ec5d-ba34-4c69-aec7-b824b9c0c2f1.pdf",
            "news_date": "2025-05-13 15:12:36"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Extract of Audited Standalone Financial Results- Copy of Newspaper Advertisement",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4d1ec233-1c2a-41d0-bfbd-799f3c585cef.pdf",
            "news_date": "2025-05-08 09:55:30"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio Recording of Jagsonpal Pharmaceuticals Limited Q4 FY25 Earnings Conference Call on May 07 2025 at 4:00 P.M.",
            "news_id": "7c1fe01a-4f6d-4545-8579-27dd459781c5",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=728b8896-d5e5-4fb3-9d6f-1d6732731aba.pdf",
            "news_date": "2025-05-07 18:40:56",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio Recording of Jagsonpal Pharmaceuticals Limited Q4 FY25 Earnings Conference Call on May 07 2025 at 4:00 P.M.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=728b8896-d5e5-4fb3-9d6f-1d6732731aba.pdf",
            "news_date": "2025-05-07 18:40:56"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Allotment of ESOP / ESPS",
            "caption": "Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS",
            "news_body": "Allotment of Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan 2022",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=77dccfdd-b45c-4f68-9d73-b59a4e1bfbec.pdf",
            "news_date": "2025-05-06 21:20:22"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Allotment of ESOP / ESPS",
            "caption": "Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS",
            "news_body": "Intimation of Grant of Employees Stock Options",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4024b991-f38d-4151-89ae-8419a647adf9.pdf",
            "news_date": "2025-05-06 20:39:17"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investors Presentation for the quarter and year ended March 31 2025",
            "news_id": "0a700ba9-581a-42e3-a082-a43e757b3e59",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9ae9ac29-12b4-46d4-a15e-11d759f2c5b4.pdf",
            "news_date": "2025-05-06 20:31:26",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investors Presentation for the quarter and year ended March 31 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9ae9ac29-12b4-46d4-a15e-11d759f2c5b4.pdf",
            "news_date": "2025-05-06 20:31:26"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Please find enclosed press release and Investor Presentation for the quarter and year ended March 31 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2107e0a7-cba9-4622-aaa0-e5ebdabac017.pdf",
            "news_date": "2025-05-06 20:25:30"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Termination Of Business Transfer Agreement - Disclosure Under Regulation 30 Of SEBI Listing Regulations",
            "news_body": "Termination of Business Transfer Agreement- Disclosure under Regulation 30 of SEBI Listing Regulations",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=661db556-84e8-4733-af38-4e231aea3b81.pdf",
            "news_date": "2025-05-06 19:56:51"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "Outcome",
            "descriptor": "Dividend",
            "caption": "Corporate Action-Board approves Dividend",
            "news_body": "The board of directors at its meeting held today has recommended a dividend of Rs. 2.5/- (125%) per equity share of face value of Rs. 2/- for the financial year ended March 31 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=97445f4b-decd-4d13-9f8c-f8a8602c43c8.pdf",
            "news_date": "2025-05-06 19:48:51"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited (Standalone) Financial Results For The Year Ended March 31 2025",
            "news_body": "Audited (Standalone) Financial Results for the year ended March 31 2025",
            "news_id": "c30da9d8-0547-4361-affa-463091c26951",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=76e0e5f4-4cad-43a8-81af-056319590215.pdf",
            "news_date": "2025-05-06 19:28:31",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "Outcome",
            "descriptor": "Financial Results",
            "caption": "Audited (Standalone) Financial Results For The Year Ended March 31 2025",
            "news_body": "Audited (Standalone) Financial Results for the year ended March 31 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=76e0e5f4-4cad-43a8-81af-056319590215.pdf",
            "news_date": "2025-05-06 19:28:31"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held On May 06 2025 Along With Audited (Standalone) Financial Results\r\nFor The Quarter And Year Ended March 31 2025",
            "news_body": "Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and Exchange Board\r\nof India (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that the\r\nBoard of Directors at its Meeting held today inter-alia considered and approved the following:\r\n1. Audited (Standalone) Financial Results along with Independent Auditors Review Report issued by the\r\nStatutory Auditors of the Company for the quarter and year ended March 31 2025.\r\n2. The Board recommended a dividend of Rs. 2.5/- (125%) per equity share having face value of Rs. 2 for the\r\nfinancial year ended March 31 2025.\r\n3. Appointment of M/s. S S Kothari Mehta & Co. Chartered Accountants as Internal Auditor of the Company\r\nfor FY 2025-26.\r\nThe Board Meeting commenced at 5:10 p.m. and concluded at 5:46 p.m.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=244ee887-299a-45a2-8d40-3e3b5f014c81.pdf",
            "news_date": "2025-05-06 18:52:59"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
            "news_body": "Intimation of Analysts/Investors Conference call on Wednesday May 07 2025 to discuss Q4 FY 25 financial results.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6f94284c-1dd5-4924-978b-81970a49f125.pdf",
            "news_date": "2025-04-30 15:13:50"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "Intimation",
            "descriptor": "Board Meeting",
            "caption": "Board Meeting Intimation for Consideration Of Financial Results For The Quarter And Year Ended March 31 2025 And Recommendation Of Dividend If Any For The Financial Year Ended March 31 2025.",
            "news_body": "Jagsonpal Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/05/2025 inter alia to consider and approve  Financial results for the quarter and year ended March 31 2025 and recommendation of Dividend if any for the financial year ended March 31 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bb005d71-eba8-44df-b285-2021be435ffb.pdf",
            "news_date": "2025-04-29 16:52:33"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Clarification On Significant Increase In The Volume",
            "news_body": "Clarification on Significant Increase in the Volume",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=de4b76b8-d219-440d-b6c3-8e88e63f6e9f.pdf",
            "news_date": "2025-04-28 12:53:27"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": " Clarification On Significant Increase In Volume Of Security Of The Company Required By NSE",
            "news_body": "Clarification on Significant increase in volume of security of the Company Required by NSE",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=40ccd608-6f94-4db2-814e-6513bd00c5fa.pdf",
            "news_date": "2025-04-28 09:10:12"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Allotment of ESOP / ESPS",
            "caption": "Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS",
            "news_body": "Allotment of Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan 2022",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6a63ae29-045a-40f5-b8b5-5a2d2537a762.pdf",
            "news_date": "2025-04-21 11:56:34"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
            "news_body": "Compliance Certificate under Reg 74(5) of SEBI (DP) Regulations 2018",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b1e6588d-2497-4435-bb8c-f0aa71bc779b.pdf",
            "news_date": "2025-04-08 13:34:19"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)",
            "news_body": "Further to our disclosure dated December 16 2023 regarding the receipt of Demand cum Show Cause Notice from the Office of the Principal Commissioner of Customs (the \"Authority\") we wish to submit that the Authority has now passed an order as detailed under Annexure-A.\r\n\r\nThe date of occurrence of event/information is the receipt of order from Office of the Principal Commissioner of Customs i.e. on April 2 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b771b2b1-8596-4126-933b-ae5d6353a2ef.pdf",
            "news_date": "2025-04-02 17:52:12"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "Intimation",
            "descriptor": "Closure of Trading Window",
            "caption": "Closure of Trading Window",
            "news_body": "Intimation of Closure of Trading Window",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d59277ed-b782-4217-8eca-47557e2b6421.pdf",
            "news_date": "2025-03-26 15:40:51"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Allotment of ESOP / ESPS",
            "caption": "Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS",
            "news_body": "Allotment of Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan 2022",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e8af9134-cff3-4c89-9b6a-3e3f1a9f2264.pdf",
            "news_date": "2025-03-13 16:23:42"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Intimation Under Regulation 30(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)",
            "news_body": "We wish to inform you that consequent to the appointment of Mr. Pratham Rawal as Company Secretary the board of directors have approved changes in KMPs authorized for purpose of determining materiality of an event or information and for the purpose of making disclosures to stock exchange (s) under the Listing Regulations.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c2692207-5c4d-450f-8079-e9a516f08455.pdf",
            "news_date": "2025-03-13 16:00:14"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Appointment of Company Secretary / Compliance Officer",
            "caption": "Appointment of Company Secretary and Compliance Officer",
            "news_body": "Appointment of Mr. Pratham Rawal as Company Secretary and Compliance Officer of the Company w.e.f. March 13 2025",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8eb8d75a-92ea-4cb7-951c-a6824a31ceba.pdf",
            "news_date": "2025-03-13 15:41:08"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Resignation of Company Secretary / Compliance Officer",
            "caption": "Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer",
            "news_body": "Please find enclosed herewith resignation submitted by Mr. Abhishek Joshi as Company Secretary and Compliance Officer & Key Managerial Personnel of the Company to pursue opportunity near my hometown.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=922d1282-ba79-430f-b140-bba7d45c8384.pdf",
            "news_date": "2025-03-03 18:59:46"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Clarification In Reference To The Corporate Announcement Filed Under Regulation 30 Of SEBI (LODR) Regulations 2015 Dated February 21 2025",
            "news_body": "Please find enlcosed herewith response to additional details required under SEBI Circular dated November 11 2024 for corporate Announcement filed under Reg. 30 SEBI LODR Regulations 2015",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4e772bcb-15cc-4381-b274-b31333716a25.pdf",
            "news_date": "2025-02-27 18:37:09"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Acquisition",
            "caption": "Announcement under Regulation 30 (LODR)-Acquisition",
            "news_body": "In compliance with Regulation 30 read with Schedule III of the Listing Regulations read with SEBI Master Circular. We wish to inform you that Jagsonpal Pharmaceuticals Limited has signed Business Transfer Agreement (BTA) acquire india business of Resilient Cosme-Ceuticals Private Limited along with the brands associated trademarks.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=506e165a-0f47-4b8e-ab28-6e279092874c.pdf",
            "news_date": "2025-02-21 19:36:49"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI LODR)",
            "news_body": "With reference to the above we wish to inform you that Company had received the warning letter dated February 05 2025 from USFDA regarding observations during the inspection of contract manufacturing facility of Jagsonpal.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=794d229d-45d4-4905-b99e-6ed3068be7dc.pdf",
            "news_date": "2025-02-21 18:23:01"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Allotment of ESOP / ESPS",
            "caption": "Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS",
            "news_body": "Pursuant to SEBI (Listing Obligation and Disclosure Requirements) Reg. 2015 as amended we are pleased to inform you that the Nomination and Remuneration Committee has issued and alloted 22150 Equity Shares of Rs. 2/ each under JPL ESOP 2022.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=11e74a1d-8c22-40bb-9ded-90625d85fe13.pdf",
            "news_date": "2025-02-17 10:34:38"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "General",
            "caption": "Intimation Under Regulation 30(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI LODR)",
            "news_body": "We wish to inform you that consequent to appointment of Mr. Sachin Jain as Chief Financial Officer of the Company. The Board has approved changes in KMPs authorised to determine materiality event or information for making disclosure.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=607bb86c-0707-4dec-9da0-be968ff70bc2.pdf",
            "news_date": "2025-02-05 12:03:15"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Change in Management",
            "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
            "news_body": "Please be informed that based on recommendation of Nomination and Remuneration Committee Audit Committee and Board at their meeting held today has approved appointment of Mr. Sachin Jain as Chief Financial Officer of the Company w.e.f February 05 2025.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c0a37eb2-1271-43ae-b97c-ec5a796d50dc.pdf",
            "news_date": "2025-02-05 11:57:47"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Reg. 30 of SEBI (LODR) Reg. 2015 please find enclosed transcript of earning call of Jagsonpal Pharmaceuticals Limited held on January 23 2025 at 10:00 AM.\r\n",
            "news_id": "99da8eb3-4f85-48f7-ac70-9c1054d0a7c9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9f4a76e6-5cad-436f-b67c-b10c9dbb5a0c.pdf",
            "news_date": "2025-01-29 13:09:20",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Earnings Call Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Reg. 30 of SEBI (LODR) Reg. 2015 please find enclosed transcript of earning call of Jagsonpal Pharmaceuticals Limited held on January 23 2025 at 10:00 AM.\r\n",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9f4a76e6-5cad-436f-b67c-b10c9dbb5a0c.pdf",
            "news_date": "2025-01-29 13:09:20"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Newspaper Publication",
            "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
            "news_body": "Please find enclosed herewith copies of advertisement published on January 24 2025 in Business Standard (English) and Business Standard (Hindi) newspaper providing extracts of Unaudited Financial Results of the Company for the quarter and nine months ended December 31 2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7c660d1c-66c9-4601-93f2-ae477ec00e97.pdf",
            "news_date": "2025-01-24 15:33:34"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Analyst / Investor Meet",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "The audio recording of the Jagsonpal Pharmaceuticals Limited Q3FY25 Earnings Conference Call held on January 23 2025 at 10:00 AM for discussion of Q3FY25 Financial Results is available on the Companys website.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=32e50aba-e08d-4571-8585-bf4455afc805.pdf",
            "news_date": "2025-01-23 19:06:25"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Integrated Filing (Financial)",
            "caption": "Integrated Filing (Financial)",
            "news_body": "Please find enclosed herewith the integrated filing (financial) for the quarter and nine- months ended December 31 2024",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=44bc372b-075e-4b9d-8ee3-a9d8451c1544.pdf",
            "news_date": "2025-01-23 18:05:53"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "General_Announcements",
            "descriptor": "Press Release / Media Release",
            "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
            "news_body": "Please find enclosed herewith a copy of the Press Release and Investor Presentation for the Unaudited Financial Results for the quarter and nine months ended December 31 2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cc273542-f0f7-4df7-82db-40fb1f88a12f.pdf",
            "news_date": "2025-01-22 19:14:38"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting Held On January 22 2025 To Consider And Approve The Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024",
            "news_body": "Please find enclosed the Unaudited Financial Results along with Limited Review Report issued by the Statutory Auditors of the Company for the quarter and nine months ended December 31 2024.",
            "news_id": "ee956a5a-9485-45f5-8f3a-79f842c7c9fb",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d2729cf2-4565-4f88-9237-7bacd28ad3c6.pdf",
            "news_date": "2025-01-22 18:13:31",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "Outcome",
            "descriptor": "Financial Results",
            "caption": "Outcome Of Board Meeting Held On January 22 2025 To Consider And Approve The Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024",
            "news_body": "Please find enclosed the Unaudited Financial Results along with Limited Review Report issued by the Statutory Auditors of the Company for the quarter and nine months ended December 31 2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d2729cf2-4565-4f88-9237-7bacd28ad3c6.pdf",
            "news_date": "2025-01-22 18:13:31"
        },
        {
            "co_code": 2171,
            "bse_code": 507789,
            "isin": "INE048B01035",
            "ann_type": "Outcome",
            "descriptor": "Outcome of Board Meeting",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held On January 22 2025 To Consider And Approve The Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024",
            "news_body": "Please find enclosed the Unaudited Financial Results along with Limited Review Report issued by the Statutory Auditors of the Company for the quarter and nine months ended December 31 2024.",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bc1aa605-02c7-4c3d-bb8e-3867aa47212a.pdf",
            "news_date": "2025-01-22 18:03:08"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Please find enclosed Transcript for the Jagsonpal Pharmaceuticals Limited Q2FY25 Earning Confrence Call held on October 24, 2024 at 11:00 AM for discussion of Q2FY25 & H1FY25 Financial Results.",
            "news_id": "d7219a1c-57c8-4e27-8d2d-6f98dad68453",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ef3c1c32-5168-43ec-a8ad-37e66505d06e.pdf",
            "news_date": "2024-10-29 17:09:22",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio Recording of Jagsonpal Pharmaceuticals Limited Q2 FY25 and H1 FY25 Earnings Conference Call on October 24, 2024",
            "news_id": "8587b175-2529-4eb7-84d3-130adb177975",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=de34dddc-f426-4706-94f4-98fc667977ec.pdf",
            "news_date": "2024-10-24 16:42:06",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "In continuation to earlier intimation dated October 23, 2024 Please find enclosed herewith revised investor presentation for quarter and half year ended September 30, 2024 due to inadvertent error in slide 20, and then same has been rectificed.",
            "news_id": "ff3f8348-833e-49c6-9c08-9965881f3f0d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ad92753b-e936-412c-86ed-a52086eaf606.pdf",
            "news_date": "2024-10-24 10:51:08",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting Held On October 23, 2024 & Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements Regulations, 2015",
            "news_body": "Please find enclosed Unaudited financial result and limited review report for quarter and half year ended September 30, 2024",
            "news_id": "92535a38-e924-4f23-8a0c-cf5d64b76309",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b4c54404-69e7-4445-9d65-05db0dcc99c9.pdf",
            "news_date": "2024-10-23 18:05:20",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting Held On August 07, 2024 Along With Unaudited Financial Results For The Quarter Ended June 30, 2024",
            "news_body": "Please find enclosed herewith Unaudited Financial Results along with limited review report for quarter ended June 30, 2024.",
            "news_id": "864d2cea-0a89-48fd-b5fe-4d5a13b15176",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e6d655ca-cea3-446d-b15f-bdb3e8dd3dd6.pdf",
            "news_date": "2024-08-07 18:42:12",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting Held On May 20, 2024 Along With Audited (Standalone) Financial Results For The Quarter And Year Ended March 31, 2024",
            "news_body": "Please find enclosed Audited Financial Result for the year ended March 31, 2024 along with Indepedent Auditors Report",
            "news_id": "591e9d69-2ac2-463c-86e0-6be20b50e433",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1c06ece6-e90f-48a3-857d-d24f6f163c29.pdf",
            "news_date": "2024-05-20 19:19:54",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting Held On February 02, 2024 Along With Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2023<BR>",
            "news_body": "Please find enclosed Unaudited Financial Results for Quarter and Nine Months ended December 31, 2023 along with limited review report  for the quarter and nine months ended December 31, 2023.",
            "news_id": "4b1626c3-d9df-4129-b199-c7b3de300db8",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5d744640-063b-46ad-a53c-697ed0e781db.pdf",
            "news_date": "2024-02-02 17:24:02",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting Held On November 03, 2023 Along With Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2023",
            "news_body": "Please enclose herewith quarterly and half yearly financial results with limited review report for the quarter and half year ended on September 30, 2023.",
            "news_id": "c9dacc4a-d35f-49e5-9431-bc3d8fb6e0a9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=51dbc89e-ca7a-4e02-a888-8d4b57239440.pdf",
            "news_date": "2023-11-03 13:58:08",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting Held On August 02, 2023 Along With Unaudited Financial Results For The Quarter Ended June 30, 2023",
            "news_body": "Kindly find enclosed the Unaudited Financial Results for the quarter ended June 30, 2023 along with Limited Review Report",
            "news_id": "4c3c4b58-e96b-48c9-b77b-c0f4aa5d849a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=041671e3-7b53-443e-b3bc-cf247db6b531.pdf",
            "news_date": "2023-08-02 18:20:33",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held On August 02, 2023 Along With Unaudited Financial Results For The Quarter Ended June 30, 2023",
            "news_body": "Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and<BR> Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we<BR> would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered<BR> and approved the Unaudited Financial Results for the quarter ended June 30, 2023. In this regard,<BR> kindly find enclosed the Unaudited Financial Results along with its Limited Review Report by the<BR> Statutory Auditors of the Company for the quarter ended June 30, 2023.",
            "news_id": "9ca177d9-dbe8-4a19-9afd-c809f13ae4d7",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f247426b-8e3d-4f2a-a784-5f4378e3f36b.pdf",
            "news_date": "2023-08-02 18:16:40",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting Held On May 23, 2023 Along With Audited (Standalone) Financial Results For The Quarter And Year Ended March 31, 2023",
            "news_body": "Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we<BR> would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered<BR> and approved the Audited (Standalone) Financial Results for the quarter and year ended March 31,<BR> 2023. In this regard, kindly find enclosed the following:<BR> 1. Audited (Standalone) Financial Results along with Independent Auditor's Review Report issued<BR> by the Statutory Auditors of the Company for the quarter and year ended March 31, 2023.<BR> 2. The Board recommended a dividend of Rs. 5/- per equity share for the financial year ended<BR> March 31, 2023.<BR> The Board Meeting commenced at 11:15 a.m. and concluded at 2:20 p.m.",
            "news_id": "83f12e7e-4506-4622-8c87-49ab55929cf5",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8c2a6d2e-2353-4ddb-81a6-41a24b667eb9.pdf",
            "news_date": "2023-05-23 14:44:44",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held On May 23, 2023 Along With Audited (Standalone) Financial Results For The Quarter And Year Ended March 31, 2023",
            "news_body": "Pursuant to Regulation 30 (read with Part A of Schedule III) and Regulation 33 of the Securities and<BR> Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we<BR> would like to inform you that the Board of Directors at its Meeting held today, inter-alia, considered<BR> and approved the Audited (Standalone) Financial Results for the quarter and year ended March 31,<BR> 2023. In this regard, kindly find enclosed the following:<BR> 1. Audited (Standalone) Financial Results along with Independent Auditor's Review Report issued<BR> by the Statutory Auditors of the Company for the quarter and year ended March 31, 2023.<BR> 2. The Board recommended a dividend of Rs. 5/- per equity share for the financial year ended<BR> March 31, 2023.",
            "news_id": "c7017c1a-24cb-4342-bb1c-91bc4decd9db",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=52bc4ba4-8ef7-4d34-af1c-d9c826a985e0.pdf",
            "news_date": "2023-05-23 14:38:00",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Results For The Quarter And Nine Months Ended 31St Dec, 2022.",
            "news_body": "Unaudited financial results quarter and nine months ended 31st dec, 2022.",
            "news_id": "fb692513-9a6e-4cad-b83b-dd9fc0a94048",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=50ddd45f-627a-46ed-991d-df42db26af73.pdf",
            "news_date": "2023-02-08 20:08:49",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transaction Under Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements Regulations, (Amendments) 2018.",
            "news_body": "Pursuant to Regulation 23(9) of the SEBI Listing Regulations, please find enclosed herewith disclosures of related party transactions on consolidated basis in the revised format, as prescribed under SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated 22 November 2021, for the half year ended commencing from 01 April, 2022 to 30 September, 2022.",
            "news_id": "d2869889-d63b-4975-b387-43fb23c8d2e5",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ca141437-c15e-42ad-8597-eaad0a333686.pdf",
            "news_date": "2022-11-24 12:23:46",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results For The Quarter And Half Year Ended 30 September, 2022.",
            "news_body": "Financial Results for the quarter and half year ended 30 September, 2022.",
            "news_id": "0d7055e2-ee85-46e7-baf6-1eaedc8b1701",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=69fa2eca-bb71-4f17-bc7a-6fe9be52e6be.pdf",
            "news_date": "2022-11-09 19:09:21",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for OUTCOME OF THE MEETING OF BOARD OF DIRECTORS OF JAGSONPAL PHARMACEUTICALS LIMITED HELD ON NOVEMBER 09TH, 2022.",
            "news_body": "OUTCOME OF THE MEETING OF BOARD OF DIRECTORS OF JAGSONPAL PHARMACEUTICALS LIMITED HELD ON NOVEMBER 09TH, 2022.",
            "news_id": "e6f4a91b-cb8d-463d-899b-aefb6b159d5e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f3a8d9da-e899-495e-8106-ca00158b0ecc.pdf",
            "news_date": "2022-11-09 19:04:33",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results For The Quarter Ended 30.06.2022",
            "news_body": "Financial results for the quarter ended 30.06.2022 along with the press release and result presentation.",
            "news_id": "e35ce2ea-7e81-494b-ae81-923d1f02c4c5",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e3e0e964-7c36-4310-b7c8-a91ab10cac80.pdf",
            "news_date": "2022-08-09 19:35:16",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transactions On Consolidated Basis For The Half Year Ended 31 March, 2022",
            "news_body": "Please find enclosed herewith disclosures of related party  transactions on consolidated basis, as prescribed under SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated 22nd November 2021, for the half year ended 31st March, 2022.",
            "news_id": "bdb95ef7-42e4-42ee-a847-10b3d696a935",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=283ea3ea-0cd8-479c-8543-de6eb316d6a3.pdf",
            "news_date": "2022-06-14 17:48:46",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results For The Quarter And Financial Year Ended 31 March, 2022.",
            "news_body": "Audited Financial Results for the quarter and financial year ended 31 March, 2022.",
            "news_id": "35b4289e-5147-43ce-98ac-730ebdb707cc",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9a77f879-fbbb-4030-a2c3-024733c29d84.pdf",
            "news_date": "2022-05-30 18:30:51",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor presentation",
            "news_id": "3ed81fd6-437c-4647-beaa-c7652c8154df",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4123fe62-8c6c-4e7a-b81f-92ff5d923e63.pdf",
            "news_date": "2022-02-21 23:50:56",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for OUTCOME OF THE MEETING OF BOARD OF DIRECTORS OF JAGSONPAL PHARMACEUTICALS LIMITED HELD ON FEBRUARY 11TH, 2022.",
            "news_body": "This is to intimate that the Board of Directors of the Company at their meeting held today, (i.e. Friday, the 11th Day of February, 2022), have inter alia, approved and taken on record the following:<BR> <BR> 1. The Un-audited Financial Results for the quarter and nine months ended 31st December, 2021; <BR> 2. Limited Review Report on the Un-audited Financial Results for the said quarter;<BR> 3. Took note of Resignation of Mr. Sanjiv Kumar Dudeja from the position of Chief Financial Officer of the Company;<BR> 4. Appointment of Mr. S.V. Subha Rao as the Chief Financial Officer with effect from 11th February, 2022;<BR> 5. Other agenda items. <BR>",
            "news_id": "1a777ff9-89e8-4e75-ad45-9fc74e27aa0d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f4ef662f-c8ff-47d5-9cd9-18df17596207.pdf",
            "news_date": "2022-02-11 13:27:03",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Under Reg 23(9) Of SEBI (LODR), 2015.",
            "news_body": "Disclosure under Reg 23(9) of SEBI (LODR), 2015.",
            "news_id": "369f811c-b310-4f72-ba01-fda8bd6a7f83",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6c4dcd85-ec72-4d73-9f37-61dc8c5f66d4.pdf",
            "news_date": "2021-11-17 17:06:39",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Standalone Un-Audited Financial Results Of The Company For The Quarter And Half Year Ended 30Th September, 2021;",
            "news_body": "Standalone Un-Audited Financial Results of the Company for the quarter and half year ended 30th September, 2021;",
            "news_id": "d6141f58-1bb8-4501-8334-fcba6ef5840a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e9f1429e-fd46-4bf3-b653-7feab53ee9c6.pdf",
            "news_date": "2021-10-19 17:25:57",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for OUTCOME OF THE MEETING OF BOARD OF DIRECTORS OF JAGSONPAL PHARMACEUTICALS LIMITED HELD ON OCTOBER 19TH, 2021",
            "news_body": "Board has approved the Unaudited Financial Results for the quarter and half year ended 30 September, 2021 . Further, the Board has also declared and approved an Interim Dividend @ 80% per Equity Shares of face value of Rs. 5/- each, i.e.  Rs. 4/- per Equity Share. <BR> The Interim Dividend shall be paid to the equity shareholders of the Company, whose names appear on the Register of Members of the Company or in the records of the Depositories as beneficial owners of the shares as on Monday, November 01, 2021 which is the Record Date fixed for the purpose.<BR> The book closure will be from 02nd November, 2021 to 3rd November, 2021 for the purpose of Interim Dividend.",
            "news_id": "1503fe11-c4f9-42d2-bfd6-826e301a12cc",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a01df083-c7b5-4a7e-8a03-3de69647e337.pdf",
            "news_date": "2021-10-19 17:17:02",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of The Board Meeting Held On 13 August, 2021.",
            "news_body": "Outcome of the Board meeting held on 13 August, 2021.<BR> The meeting was concluded at 1855 hours.",
            "news_id": "f9d04a1f-86ad-43c4-b6e0-344a6b76c7e3",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6ff5d6fc-0c3f-4c1b-b820-0ac3b0086df5.pdf",
            "news_date": "2021-08-13 19:11:17",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transaction Under Regulation 23(9) Of The SEBI (Listing Obligations And Disclosure Requirements Regulations, (Amendments) 2018 For The Financial Year Ended 31 March, 2021.",
            "news_body": "Pursuant to Regulation 23 (9) of the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2018, please find enclosed disclosure of Related Party Transaction, in the format specified in the Accounting Standard for the financial year ended March 31, 2021.<BR> <BR> This is for your information and records.",
            "news_id": "c657f94d-0023-46b1-b28e-fe8ad4c47bfb",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ea7be2e1-f813-4144-aa8a-5f924c0a80fe.pdf",
            "news_date": "2021-07-29 12:19:57",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of The Board Meeting",
            "news_body": "Outcome of the Board Meeting",
            "news_id": "cf51021d-526a-4730-8714-1ff0f804084a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1e3f039b-22a0-449c-9801-8dc346db072b.pdf",
            "news_date": "2021-06-30 16:18:20",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results For The Quarter And Year Ended 31.03.2021.",
            "news_body": "OUTCOME OF THE MEETING OF BOARD OF DIRECTORS OF JAGSONPAL PHARMACEUTICALS LIMITED HELD ON JUNE 30TH, 2021.",
            "news_id": "ab748b4d-4fdc-4301-9c35-494f1c8324fc",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9fdb74ae-e7d6-467e-ad4d-63c00d35362a.pdf",
            "news_date": "2021-06-30 16:12:42",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "JAGSNPHARM",
            "disp": "Jagsonpal Pharmaceuticals",
            "bse_code": 507789,
            "isin": "INE048B01035",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results For The Quarter Ended 31 December, 2020.",
            "news_body": "Financial Results for the quarter ended 31 December, 2020.",
            "news_id": "e62e72fa-fbb5-46e1-a8d3-4a8af2dc3abb",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=37fcc7fd-07c0-4e78-9de4-4d85fdc3387b.pdf",
            "news_date": "2021-02-12 14:48:11",
            "seo": "jagsonpal-pharmaceuticals-ltd",
            "ltp": 183.13,
            "ch": -1.460000000000008,
            "pch": -0.7909420878704199,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 4410,
            "exch": "NSE",
            "seg": "E"
        }
    ]
}